Reading OCGN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OCGN free→Reading OCGN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OCGN free→QuarterlyIQ Insights · OCGN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Chief Accounting Officer — Ramesh Ramachandran: The Chief Accounting Officer resigned and was replaced by the existing Chief Financial Officer.
of this Current Report on Form 8-K is incorporated herein by reference. The Company offered and sold the additional notes to the initial purchaser in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and for resale by the initial purchaser to persons reasonably believed to be qualified institutional buyers pursuant to the exemption from registration provided by Rule 144A under the Securities Act. The Compa…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously reported, on May 7, 2026, Ocugen, Inc. (the “Company”) completed the closing under its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”). The notes were issued pursuant to an indenture, dated May 7, 2026 (the “Indenture”), between the Company and U.S. Bank Trus…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective May 8, 2026, Huma Qamar, M.D., MPH, CMI, separated from Ocugen, Inc. (the “Company”) as its Chief Medical Officer.
Unregistered Sales of Equity Securities. The information set forth under
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under
is an estimate based on information available to management as of the date of this Current Report on Form 8-K, has not been reviewed or audited by the Company’s independent registered accounting firm, and is subject to change. It is possible that the final results may differ from the preliminary unaudited information provided, including differences due to the completion of the financial closing procedures; changes in facts, circumstances and/or assumptions and/or developments in the interim.…
Termination of a Material Definitive Agreement. The information set forth under
Entry Into a Material Definitive Agreement. Indenture and Notes On May 7, 2026, Ocugen, Inc. (the “Company”) completed its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”). The notes were issued pursuant to an indenture, dated May 7, 2026 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee. The notes are general unsecured obligations of t…
Unregistered Sales of Equity Securities. The information set forth under
Results of Operations and Financial Condition. On May 5, 2026, Ocugen, Inc (the “Company”) issued a press release announcing certain financial results for the quarter ended March 31, 2026. The Company has scheduled a conference call and webcast for 8:30 a.m. Eastern Time on May 5, 2026, to discuss these financial results and business updates. The Company will use presentation materials in connection with the conference call and webcast, which presentation materials will be posted on the Compa…
Other Events. On May 5, 2026, the Company announced the pricing of its previously announced private offering (the “Offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “Notes”). The Company has also granted to Oppenheimer & Co. Inc. (the “Initial Purchaser”) an option to purchase, for settlement within a 13-day period from the date of initial issuance of the Notes, up to an additional $15.0 million aggregate principal amount of the Notes. The…
Results of Operations and Financial Condition. On May 4, 2026, Ocugen, Inc. (the “Company”) announced its intention to offer, subject to market conditions and other factors, $115 million aggregate principal amount of convertible senior notes due 2034 (the “Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A promulgated under the Securities Act of 1933, as amended (the “Offering”). In connection with the Offering, the Company provided the disclosure attached…
of this Form 8-K, including Exhibit 99.1, attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference in any filing with the U.S. Securities and Exchange Commission, whether made by the Comp…
Other Events. As previously disclosed, in August 2025, Ocugen, Inc. (“Ocugen”) closed a registered direct offering, pursuant to a securities purchase agreement with an institutional investor (the “Investor”), for the purchase and sale of 20,000,000 shares of common stock, $0.01 par value per share (“Common Stock”), and warrants to purchase up to an aggregate of 20,000,000 shares of Common Stock. On March 12, 2026, the Investor purchased 10,000,000 shares of Common Stock upon the partial exerc…
Other Events. On February 12, 2026, Ocugen, Inc. (the “Company”) filed a petition (the “Petition”) in the Court of Chancery of the State of Delaware pursuant to Section 205 of the Delaware General Corporation Law (the “DGCL”) seeking validation of the Certificate of Amendment (as defined below), increasing the Company’s number of authorized shares of common stock, and all shares of the Company’s common stock issued in reliance on the effectiveness and validity thereof. Concurrently with the f…
Results of Operations and Financial Condition. On March 4, 2026, Ocugen, Inc. (the “Company”) issued a press release announcing certain financial results for the fourth quarter and the fiscal year ended December 31, 2025. The Company has scheduled a conference call and webcast for 8:30 a.m. Eastern Time on March 4, 2026, to discuss these financial results and business updates. The Company will use presentation materials in connection with the conference call and webcast, which presentation ma…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Financial Officer and Principal Financial Officer On February 9, 2026, Ocugen, Inc. (the “ Company ”) announced the appointment of Rita Johnson-Greene as the Company’s Chief Financial Officer, effective February 9, 2026. The Board of Directors of the Company appointed Ms. Johnson-Greene to serve as the Company’s principal finan…
Other Events. On January 22, 2026, the Company closed the Offering and anticipates the proceeds from the Offering will extend its cash runway into the fourth quarter of 2026. Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve estimates, assumptions, risks and uncertainties. Forward-looking statements include, but are not limited to, statements related to the Company’s anticipated cash runway. The risks and unce…
Other Events. On January 21, 2026, the Company issued a press release announcing it had priced the Offering. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve estimates, assumptions, risks and uncertainties. Forward-looking statements include, but are not limited to, statements relat…
Entry into a Material Definitive Agreement. On January 20, 2026, Ocugen, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Oppenheimer & Co. Inc. (the “ Underwriter ”), pursuant to which the Company agreed to issue and sell to the Underwriter, in an offering (the “ Offering ”) 15,000,000 shares of the Company’s common stock, par value $0.01 per share (the “ Common Stock ”), at an offering price of $1.50 per share (the “ Offering Price ”). The…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In the fourth quarter of 2025, the Compensation Committee (the “ Compensation Committee ”) of the Board of Directors (the “ Board ”) of Ocugen, Inc. (the “ Company ”) conducted a review, with its compensation consultant, of total equity ownership of the Company’s Chief Executive Officer, Dr. Shankar Musunuri, as compared to founder chief executive…
Results of Operations and Financial Condition. On November 5, 2025, Ocugen, Inc. (the "Company") issued a press release announcing certain financial results for the quarter ended September 30, 2025. The Company has scheduled a conference call and webcast for 8:30 a.m. Eastern Time on November 5, 2025, to discuss these financial results and business updates. The Company will use presentation materials in connection with the conference call and webcast, which presentation materials will be post…
Termination of a Material Definitive Agreement. As previously disclosed, on June 22, 2025, Ocugen, Inc. (“Ocugen” or the “Company”) and OrthoCellix, Inc., a Delaware corporation and wholly-owned subsidiary of the Company to which the Company has contributed the assets related to the Company’s Neocart product candidate (“OrthoCellix”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among Ocugen, OrthoCellix, Carisma Therapeutics Inc., a Delaware corporation (“Car…
Entry Into a Material Definitive Agreement. On September 11, 2025, Ocugen, Inc. (“Ocugen” or the “Company”), entered into an Exclusive License Agreement (the “Agreement”) with Kwangdong Pharmaceutical Co., Ltd. (“Kwangdong”), pursuant to which Kwangdong was granted an exclusive, non-sublicensable, royalty-bearing license to (i) import, export, distribute, use, have used, keep, sell, have sold, or offer for sale, including to research, develop, commercialize, register, modify, enhance, improve…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.